From: Treatment effect prediction with adversarial deep learning using electronic health records
Characteristics | No. of participants (n = 2930) | MACE (n = 752) | Non-MACE (n = 2178) | P-value |
---|---|---|---|---|
Age (years), mean (SD) | 62.27 ± 12.11 | 67.12 ± 11.95 | 60.60 ± 11.71 | <  0.001 |
Female sex (T/F) | 2080/850 | 528/225 | 1552/625 | 0.573 |
Hypertension (T/F) | 1981/949 | 537/215 | 1444/734 | 0.011 |
Diabetes mellitus (T/F) | 1986/803 | 482/224 | 1504/439 | <  0.001 |
Hypercholesterolemia (T/F) | 2362/568 | 623/129 | 1739/439 | 0.082 |
Previous PCI (T/F) | 816/2114 | 214/538 | 602/1576 | 0.701 |
Previous CABG (T/F) | 86/2844 | 38/714 | 48/2130 | <  0.001 |
ST-segment elevations ECG (T/F) | 106/2824 | 27/725 | 79/2099 | 0.947 |
BMI (kg/m2), mean (SD) | 25.90 ± 11.30 | 25.50 ± 12.73 | 26.03 ± 10.76 | 0.333 |
CCR (ml/min/ m2), mean (SD) | 78.73 ± 38.19 | 85.36 ± 48.30 | 76.41 ± 33.65 | <  0.001 |
CKMB (umol/L), mean (SD) | 9.49 ± 14.95 | 9.30 ± 11.45 | 9.56 ± 16.09 | 0.715 |
Treatment | ||||
 Coronary angiography (T/F) | 993/1937 | 270/482 | 723/1455 | 0.191 |
 Nitroglycerin (T/F) | 904/2026 | 292/460 | 612/1566 | <  0.001 |
 Vasodilator (T/F) | 951/1979 | 305/447 | 646/1532 | <  0.001 |
 Antihypertensive therapy (T/F) | 1375/1555 | 385/367 | 990/1188 | <  0.001 |
 Hypoglycemic therapy (T/F) | 451/2479 | 127/625 | 324/1854 | 0.208 |
 Lipid lowering therapy (T/F) | 511/2419 | 129/623 | 382/1796 | 0.854 |
 Blood transfusion (T/F) | 91/2839 | 28/724 | 63/2115 | 0.312 |
 Quick-acting rescue (T/F) | 796/2134 | 236/516 | 560/1618 | <  0.001 |
 Aspirin (T/F) | 730/2200 | 204/548 | 526/1652 | 0.114 |
 Antiarrhythmia (T/F) | 114/2816 | 45/707 | 69/2109 | <  0.001 |
 Anti-angina (T/F) | 1216/1714 | 376/376 | 840/1338 | <  0.001 |
 Antiplatelet (T/F) | 933/1997 | 255/497 | 678/1500 | 0.172 |